19 May BioEclipse Therapeutics™ Announces Move to New Corporate Headquarters in Mountain View, CA
Mountain View, CA – May 19, 2020 – BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company committed to developing first-in-class, curative immuno-oncology therapeutics, today announced that it has established operations at a new corporate headquarters and laboratory facilities at the Open Medicine Institute (OMI) Collaboratory, a 104,000 square-foot facility in Mountain View, CA. The company has relocated from its previous location, Johnson & Johnson Innovation – JLABS in South San Francisco, a premier life science incubator program where BioEclipse took up residence in August 2017.
The move into its new headquarters kicked off a year in which BioEclipse expects to advance into human clinical trials with its investigational drug candidate CRX100, a patented, first-in-class, intravenously delivered, targeted, multi-mechanistic cancer immunotherapy.
Pamela Contag, Ph.D., founder and CEO of BioEclipse, stated, “BioEclipse was a resident company at Johnson & Johnson Innovation – JLABS in South San Francisco for more than two years as we prepared for our Phase 1 clinical trial. We graduated from the JLABS program in February 2020, and we will always be grateful for the expertise, connections and team energy that catalyzed our growth to a clinical-stage company. Our new space includes two new laboratories and will provide an inspiring work environment for employees, helping to foster a strong culture of innovation and collaboration as we advance CRX100 into clinical trials and bring about the next generation of cancer immunotherapies.”
Developed using technology patented exclusively from Stanford University, CRX100 has the potential to provide a curative therapy to patients with a broad range of solid and liquid tumors, including hard to treat cancers and some pediatric cancers. The immunotherapy pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. These two drug substances, when used separately, display limited efficacy as cancer therapies, but when combined in preclinical models of disease, create a treatment capable of not only eradicating cancer cells, but also protection from relapse, through a durable immune response that prevents the recurrence of the cancer.
The BioEclipse activated immune cells pre-infected with a selective oncolytic virus have demonstrated compelling results in preclinical studies. BioEclipse completed a Series A-1 funding round in June 2019. The company received clearance in April 2020 from the U.S. Food and Drug Administration of an Investigational New Drug (IND) application for CRX100 and plans to initiate a Phase 1 clinical trial in therapy-refractory solid tumors in 2020.
About BioEclipse Therapeutics™
BioEclipse Therapeutics™ is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immuno-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique multi-mechanistic combination approach could address needs of patients with cancers believed to be untreatable. BioEclipse Therapeutics™ is preparing to initiate a Phase 1 clinical trial, CRX100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers. For more information, visit www.bioeclipse.com.
About Open Medicine Institute
Open Medicine Institute is a community-based, data-driven independent research institute located in the heart of Silicon Valley. OMI HQ features the OMI Collab, a 104,000 square foot former pharmaceutical campus with state-of-the-art laboratories and research facilities, including a clinical (CLIA) lab, Bio Lab, BSL 1/2 and 3 ready lab space, two biobanks and a host of shared resources and lab cores. The Collab opened in January of 2019 and hosts over 30 organizations from individual investigators up to Series B companies, representing over $300 million in invested capital. For more information contact: collab@openmedicineinstitute.org .
Contacts:
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
212-375-2694
mmiller@tiberend.com
Johanna Bennett (Media)
212-375-2686
jbennett@tiberend.com